10 January 2023 in Frontiers in Neurology
Background: Acute ischemic stroke (AIS), the most common type of stroke, is a major cause of morbidity and mortality worldwide. A growing number of studies have demonstrated that inflammation is a critical mechanism in AIS. Being an easily available and effective inflammatory marker, the systemic inflammation response index (SIRI) shows a high association with mortality in patients with cancer and intracerebral hemorrhage. In this study, we evaluated the potential prognostic role of SIRI in critically ill patients with AIS.Methods: Clinic data were extracted from the Medical Information Mart data for the Intensive Care IV (MIMIC-IV) database. The optimal cutoff value of SIRI was determined by X-tile software. The primary outcome was the 90-day all-cause mortality, and the secondary outcomes were 30-day and 1-year all-cause mortality of patients with AIS. Cox proportional hazards regression analyses were used to assess the association between SIRI levels and all-cause mortality, and survival curves were estimated using the Kaplan–Meier method. Furthermore, a 1:1 propensity score matching (PSM) method was performed to balance the influence of potential confounding factors.Results: A total of 2,043 patients were included in our study. X-tile software indicated that the optimal cutoff value of the SIRI for 90-day mortality was 4.57. After PSM, 444 pairs of score-matched patients were generated. Cox proportional hazard model showed that after adjusting for possible confounders, high SIRI level (≥4.57) was independently associated with the 90-day all-cause mortality in the cohort before PSM (HR = 1.56, 95% CI: 1.30–1.89, p < 0.001) and the PSM subset (HR = 1.47, 95% CI: 1.16–1.86, p = 0.001). The survival curves showed that patients with SIRI ≥4.57 had a significantly lower 90-day survival rate in the cohort before PSM (56.7 vs. 77.3%, p < 0.001) and the PSM subset (61.0 vs. 71.8%, p = 0.001). Consistently, AIS patients with high SIRI levels (≥4.57) presented a significantly high risk of 30-day and 1-year all-cause mortality before and after PSM.Conclusion: A higher SIRI (≥4.57) was associated with a higher risk of 90-day, 30-day, and 1-year mortality and was an independent risk factor of mortality in patients with acute ischemic stroke.
1 January 2025 in International Journal Of Clinical Practice
Background: The role of mitochondria‐related genes on non‐small‐cell lung cancer (NSCLC), which encompasses lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), remains inadequately understood. This study investigates their influence on prognosis, immune microenvironment, and response to immunotherapy. Methods: We analyzed NSCLC data from The Cancer Genome Atlas to assess gene expression differences, Kaplan–Meier survival curves, and Cox regression. A prognostic model was developed using machine learning techniques. Functional enrichment and pathway analyses were performed using Gene Ontology, the Kyoto Encyclopedia of Genes and Genomes, and Gene Set Enrichment Analysis. Single‐cell RNA sequencing data from the TISCH2 database were examined to elucidate key gene expressions. Tumor Mutation Burden and differential mutation frequencies were evaluated. The ESTIMATE and TIDE algorithms were utilized to analyze the immune microenvironment and predict responses to immunotherapy. Results: Significant mitochondria‐related genes were identified in both LUAD and LUSC. The StepCox [both] + Ridge model, which included 13 genes, exhibited the highest prognostic accuracy. Functional analyses indicated that these genes are involved in KRAS signaling, angiogenesis, and glycolysis. Single‐cell analysis revealed that KLK6 expression is primarily localized in malignant and epithelial cells. Mutation analysis indicated that PTEN and ASPM mutations were more prevalent in low‐risk groups, whereas CACNA1C and CSMD1 mutations were more common in high‐risk groups. Nine genes showed strong correlations with immune scores. TIDE analysis suggested that high‐risk patients may have a better response to immunotherapy, a finding corroborated by submap analysis in high‐risk LUSC patients. Conclusion: Mitochondria‐related genes significantly impact the prognosis of NSCLC and may influence the immune microenvironment and responses to immunotherapy. These findings enhance our understanding of NSCLC and suggest potential targets for future therapeutic interventions.